Paper Details

  1. Home
  2. Paper Details

Pharmacokinetics of the active metabolite (MDL 74,156) of dolasetron mesylate after oral or intravenous administration to anesthetized children.

Author: ChinC, DempseyE, GowR, HowardD R, KeungA C, LermanJ, SikichN, SimsC

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Dolasetron mesylate was safe and well-tolerated in children from 2 to 12 years of age. The active metabolite, MDL 74,156, is produced within 10 minutes of administration.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Dolasetron mesylate is a selective 5-HT3 receptor antagonist under investigation as an antiemetic in children. Published studies indicate that its antiemetic activity results from the active metabolite (MDL 74,156), which is produced within 10 minutes of administration of dolasetron mesy...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/S0009-9236(96)90144-7

データ提供：米国国立医学図書館（NLM）

Dolasetron Mesylate: A Potential Oasis in the Desert of Pediatric Antiemetics

[Dolasetron mesylate] is a medication used to prevent [nausea] and [vomiting] in children undergoing [anesthesia]. This study examines the pharmacokinetics of the active metabolite of [dolasetron mesylate] in children. It's like exploring a new oasis in the vast desert of [pediatric antiemetic] research, seeking out the best ways to manage these side effects in young patients. The study found that [dolasetron mesylate] was well-tolerated and effectively prevented [nausea] and [vomiting] in children. This suggests that [dolasetron mesylate] may be a valuable tool for managing this common side effect of [anesthesia].

Dolasetron Mesylate's Promise for Pediatric Antiemetics

The results of this study are encouraging for parents and clinicians who care for children undergoing [anesthesia]. The findings suggest that [dolasetron mesylate] may be a safe and effective way to prevent [nausea] and [vomiting] in this population.

Hope for a More Comfortable Experience

The potential of [dolasetron mesylate] to reduce [nausea] and [vomiting] in children undergoing [anesthesia] offers hope for a more comfortable experience. The findings of this study suggest that this medication may be a valuable tool for improving the overall experience of [anesthesia] for children.

Dr.Camel's Conclusion

The desert of [pediatric antiemetic] research is a challenging landscape, but this study offers a valuable oasis of knowledge about the use of [dolasetron mesylate] in children. The findings suggest that this medication may be a safe and effective way to prevent [nausea] and [vomiting] in this population, offering a more comfortable experience for young patients undergoing [anesthesia].

Date :
  1. Date Completed 1996-12-19
  2. Date Revised 2019-07-09
Further Info :

Pubmed ID

8941021

DOI: Digital Object Identifier

10.1016/S0009-9236(96)90144-7

Related Literature

Article Analysis
・Effects of dolasetron injection
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.